InMed Pharmaceuticals (INM) Depreciation & Amortization (CF) (2019 - 2026)

InMed Pharmaceuticals' Depreciation & Amortization (CF) history runs 8 years deep, the most recent figure standing at $50509.0 for Q1 2026.

• On a quarterly basis, Depreciation & Amortization (CF) fell 3.43% year-over-year to $50509.0 in Q1 2026; TTM through Mar 2026 was $209664.0, a 2.42% decrease from a year earlier, with the FY2025 full-year figure at $212839.0, down 3.08% from the prior year.
• Depreciation & Amortization (CF) retreated to $50509.0 in Q1 2026 per INM's latest filing, from $53201.0 in the prior quarter.
• Across five years, Depreciation & Amortization (CF) topped out at $55231.0 in Q4 2023 and bottomed at $49048.0 in Q3 2022.
• The 5-year median for Depreciation & Amortization (CF) is $53203.0 (2024), against an average of $52878.1.
• Across the five-year window, Depreciation & Amortization (CF) soared 94.52% in 2022 and declined 4.97% in 2023, its largest moves.
• Year by year, Depreciation & Amortization (CF) stood at $49049.0 in 2022, then increased by 12.6% to $55231.0 in 2023, then decreased by 3.67% to $53203.0 in 2024, then declined by 0.0% to $53201.0 in 2025, then fell by 5.06% to $50509.0 in 2026.
• Per Business Quant, the three latest INM Depreciation & Amortization (CF) figures stand at $50509.0 (Q1 2026), $53201.0 (Q4 2025), and $53202.0 (Q3 2025).